Expanding role of nuclear medicine in cardiac amyloidosis: insights from the EJNMMI collection.
Authors
Affiliations (2)
Affiliations (2)
- Division of Nuclear Medicine, Department of Radiology, SSM Health Saint Louis University Hospital, St. Louis, MO, USA. [email protected].
- Division of Nuclear Medicine, Department of Radiology, SSM Health Saint Louis University Hospital, St. Louis, MO, USA.
Abstract
Recent advances in nuclear medicine are reshaping the evaluation of cardiac amyloidosis, as highlighted by the recent collection published in EJNMMI (collection link: https://link.springer.com/collections/igfdhcddjg). This commentary summarizes key insights from these studies, emphasizing the evolving shift from conventional diagnostic imaging toward a more integrated and comprehensive approach. Emerging developments include novel amyloid PET tracers, improved diagnostic accuracy with SPECT/CT, multimodality imaging strategies, and enhanced assessment of systemic disease burden extending beyond the left ventricle. There is also growing interest in longitudinal monitoring, pre-symptomatic detection, and the role of artificial intelligence. Together, these advances position nuclear medicine as an essential tool for disease characterization, risk stratification, and treatment assessment.